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Oral Presentations S185was observed in one patient. The overall survival of these patients
was 94% with a median follow up of 2.8 years (range, 0.2-12 years).
The causes of death were infection and complications of aGVHD.
These results demonstrate the usefulness of using HSCT in the
non-SCID population and absence of an MRD should not delay
HSCT. We conclude that HSCT should be considered early and
prior to the onset of significant morbidity in non-SCID PIDs.85
IMPROVED CLINICAL OUTCOME OF HIGH RISK b THALASSEMIA MAJOR
PATIENTS UNDER GOING A HLA MATCHED RELATED ALLOGENEIC
STEM CELL TRANSPLANT WITH THE USE OF A TREOSULPHAN BASED
CONDITIONING REGIMEN
Mathews, V., George, B., Lakshmi, K.M., Abraham, A., Ahmed, R.,
Viswabandya, A., Srivastava, A. Christian Medical College, Vellore,
Tamil Nadu, India
The clinical outcome post allogeneic SCT in patients with b thal-
assemia major (TM) who belong to the Class III and the Class III
high risk group (defined by us previously; BBMT 2007;13:889),
remains poor.
From August 2009 we used a Treosulphan based conditioning
regimen (thiotepa: 8 mg/kg on day-6, treosulphan: 14gm/m2 for 3
days from day -5 to -3 and fludarabine 40mg/m2 for 4 days from
day -5 to -2) in an effort to improve the clinical outcome in these sub-
sets. 18 patients have since then had this conditioning regimen at our
center. The median age was 10 years (range: 2 – 17) and the median
liver size was 6 cm (range: 2-10). 15 (83.3%) were Class III while 10
(55%) wereClass III high risk (age$ 7 years and liver size$ 5cms). 3
were HCV positive, 2 were having a second SCT and 4 patients had
a prior splenectomy. All patients had HLA identical related donors.
Bone marrow was the source of stem cells in 14 (77%) while the rest
had PBSC. Themedian TNCdose was 3.95x108/kg (range: 2.5-8.4).
All 18 patients engrafted (ANC . 500/mm3) at a median of 17 days
(range: 11 – 22). Features suggestive of a SOSwere seen in 4 patients,
of whom 2 subsequently died on day 41 and 44 respectively (second-
ary to sepsis and multi-organ failure). In 7 patients there was tran-
sient hypoxia, the etiology of which could not be explained by
routine tests and imaging. DAH occurred in 4 of these cases and 2
of them (who also had features of SOS) succumbed to subsequent
complications. Besides the two deaths an additional patient has had
secondary graft failure on day 76 (with autologous recovery). Of
the remaining 15 patients a day 28 chimerism (VNTR assay) study
revealed complete chimerism in 10 (66%) while 4 had donor chime-
rism over 90% and over the next fewmonths improved further (none
require blood transfusions). 4 (27%) of the 15 patient who could be
evaluated developed acute GVHD which was grade III/IV in one
case. In comparison to our previously reported data among the entire
Class III and the Class III high risk subset who had an EFS of
70.366% and 2467% respectively (BBMT 2007), these results are
a significant improvement.
In conclusion a treosulphan based conditioning regimen is well
tolerated in high risk patients with TM. While the incidence of
SOS is very low compared to that seen with a conventional busul-
phan based regimen there remains some concern about the high in-
cidence of pulmonary complications that was noted in this cohort.86
RISK STRATIFICATION WITHOUT A LIVER BIOPSY OF PATIENTS WITH
b THALASSEMIA MAJOR UNDER GOING A MATCHED RELATED ALLOGE-
NEIC BONE MARROW TRANSPLANT
Mathews, V., Lakshmi, K.M., Abraham, A., Ahmed, R.,
Viswabandya, A., George, B., Srivastava, A. Christian Medical College,
Vellore, TN, India
Conventional risk stratification of patients with b thalassemia ma-
jor (TM) prior to an allogeneic SCT requires a liver biopsy. 288 pa-
tients with TM underwent a SCT at our center. The median age was
7 years (range: 2-24). By the conventional risk stratification, 14
(4.9%)wereClass I while 142 (49.3%)wereClass III.Myelo-ablative
conditioning regimen in the majority was busulphan based (oral).
284 (98.6%) received a bone marrow graft. At a median follow up
of 49 months (range: 2-213) the 5 year Kaplan-Meir estimate ofoverall survival (OS) and event free survival (EFS) was 71.362.8%
and 64.762.9% respectively. On a univariate analysis factors associ-
ated with an adverse impact on EFS were patients’ age, donor age,
liver size, serum AST level, serum ferritin level, palpable spleen
and splenectomy. On a multivariate analysis only liver size retained
its significant adverse impact. Since the majority of our patients be-
longed to Class III and we had earlier shown that age $ 7 years and
liver size$ 5 cms had a significant adverse impact in this group, even
on a multivariate analysis (BBMT 2007) we used these numbers to
dichotomize the group. Of the remaining factors that had an adverse
impact on EFS, donor age (significant correlation with recipient age)
and splenectomy (small number) were excluded. The median values
of the serumAST ($ 50U/Lt) and ferritin ($ 3000mg/Lt) levels were
then also used to dichotomise the group. On a cox-regression anal-
ysis liver size $ 5cms (RR 5 2.8; P 5 0.000), age $ 7 years (RR 5
2; P 5 0.004), serum ferritin $ 3000mg/Lt (RR 5 1.6; P 5 0.029)
and a palpable spleen (included those that had splenectomy) (RR
5 2.2; P 5 0.004) were significant. Scores were generated for each
of the above adverse factors proportional to the relative risk as illus-
trated in Table 1. The total score could therefore range form 0 to 9
for each patient. Kaplan-Meir estimates of EFS were generated for
each of these scores and clustered into groups. Three groups could
be recognized; Group A with a score # 2 (n 5 121 [42%]), Group
B 5 . 2 to \ 9 (n 5 118 [41%]) and Group C 5 9 (n 5 48
[17%]). Kaplan-Meir estimates of EFS and cumulative risk of rejec-
tion between these groups was significantly different (P5 0.000 and
0.007 respectively)
The proposed risk stratification does not require a liver biopsy, has
a good distribution of cases in the defined groups and better
identifies a high risk subset of patients than the conventional risk
stratification system.
Table 1. Scoring systemVariable/Score 0 2 3
Liver Size (cm) <5 $ 5
Age (years) <7 $ 7
Serum Ferrtin (mg/Lt) <3000 $ 3000
Spleen palpable No Yes/Post splenectomy87
DIFFERENTIAL IMPACT OF HLA-A, -B, AND -DRB1 MISMATCHING IN RE-
LATION TO OTHER VARIABLES ON THE OUTCOMES OF MYELOABLATIVE
UNRELATED SINGLE DONOR UMBILICAL CORD BLOOD TRANSPLANTA-
TION FROM 4/6 MATCHED UNITS IN CHILDREN AND YOUNG ADULTS
Prasad, V.K.1, Mendizabal, A.2, Tewari, P.1, Page, K.1, Parikh, S.H.1,
Szabolcs, P.1, Driscoll, T.A.1, Martin, P.L.1, Kurtzberg, J.1 1Duke
University Medical Center, Durham, NC; 2The EMMES Corporation,
Rockville, MD
Background: Use of 4/6 matched cord blood units (CBU) substan-
tially expands the chances of finding a suitable donor for patients
lacking an adult match. An understanding of the impact of locus-spe-
cific HLA mismatching, cellular characteristics of CBU and other
variables will help optimize CBU selection and further improve out-
comes of 4/6 unrelated cord blood transplant (UCBT).
Methods: All recipients (age # 21yrs) of myeloablative UCBT be-
tween 08/1993 and 11/2007 at Duke from single 4/6 matched
(low-res HLA-A and B; high-res DRB1) CBU were studied (median
follow-up 6.9 years; range, 0.9-15.1). Of 314 patients (median age 6.1
years; range 0.1-20.3), 63% were male, 27% non-Caucasian, 38%
CMV positive, and 61% transplated for malignancy. Statistics in-
cluded Kaplan-Meier (KM), log-rank, and Cox models. Prognostic
factors were assessed in univariate KM analyses of overall survival
(OS) and cumulative incidence (C_Inc) of engraftment and
GVHD. Cox proportional hazards models were constructed using
stepwise selection. P-values\ 0.05 were statistically significant in
multivariate model. Median (range)/kg of cryopreserved TNC, rein-
fused TNC, CD34, and CFU doses were 6.2(0.9-38.2)x107, 4.8(0.5-
27.4)x107, 1.8(0.02-105)x105, and 3.6(0-50)x104, respectively.
RESULTS: Primary graft failure and autologous recovery occurred
in 21 (6.7%) and 10 (3.2%). C_Inc of grades III-IV acuteGVHDand
chronic GVHD at 1 year was 13.6%(95%CI, 9.8%-17.4%) and
13.9%(95%CI, 9.9%-17.9%). OS at 1 year and 3 years were
54.8%(95%CI, 49.1%-60.1%) and 47.5%(95%CI, 41.8%-52.9%),
